1. Home
  2. HUT vs COGT Comparison

HUT vs COGT Comparison

Compare HUT & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hut 8 Corp.

HUT

Hut 8 Corp.

HOLD

Current Price

$53.29

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$37.98

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUT
COGT
Founded
2011
2014
Country
US
US
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.5B
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
HUT
COGT
Price
$53.29
$37.98
Analyst Decision
Strong Buy
Buy
Analyst Count
15
15
Target Price
$56.00
$33.50
AVG Volume (30 Days)
5.0M
1.8M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
672.73
N/A
EPS
0.49
N/A
Revenue
$162,385,000.00
$7,871,000.00
Revenue This Year
$74.79
N/A
Revenue Next Year
$116.78
$506.58
P/E Ratio
$109.47
N/A
Revenue Growth
97.64
N/A
52 Week Low
$10.04
$3.72
52 Week High
$66.07
$43.73

Technical Indicators

Market Signals
Indicator
HUT
COGT
Relative Strength Index (RSI) 48.29 52.47
Support Level $49.58 $36.03
Resistance Level $55.20 $39.82
Average True Range (ATR) 5.03 1.85
MACD -0.53 0.03
Stochastic Oscillator 48.34 55.09

Price Performance

Historical Comparison
HUT
COGT

About HUT Hut 8 Corp.

Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: